sorafenib has been researched along with Necrosis in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.23) | 29.6817 |
| 2010's | 28 (90.32) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Huang, Y; Li, X; Wang, J; Xu, L; Yu, H; Zhang, F; Zhuge, Y; Zou, X | 1 |
| Jakubowicz-Gil, J; Langner, E; Maciejczyk, A; Rzeski, W; Skalicka-Woźniak, K; Sumorek-Wiadro, J; Zając, A | 1 |
| Chen, D; Eyupoglu, IY; Savaskan, N | 1 |
| Augustyns, K; Bräsen, JH; Feldmann, F; Fulda, S; Goossens, V; Hofmans, S; Jeong, M; Joossens, J; Lee, EW; Linkermann, A; Martens, S; Song, J; Takahashi, N; Tonnus, W; Van der Veken, P; Vandenabeele, P | 1 |
| Abegg, VF; Bouitbir, J; Grünig, D; Krähenbühl, S; Mingard, C; Paech, F | 1 |
| Fulda, S | 1 |
| Avritscher, R; Bankson, JA; Cortes, AC; Ensor, JE; Kingsley, CV; Maldonado, KL; Minhaj, AA; Mitchell, JM; Muñoz, NM; Polak, U; Rashid, A; Taghavi, H | 1 |
| Kadastik, Ü; Lavogina, D; Lavrits, A; Meltsov, A; Peters, M; Rinken, A; Salumets, A; Samuel, K; Sõritsa, D | 1 |
| Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Righi, M; Saba, E | 1 |
| Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I | 1 |
| Anichini, A; Carbone, A; Carlo-Stella, C; Cleris, L; Locatelli, SL; Malorni, W; Pierdominici, M; Saba, E; Stirparo, GG; Tartari, S | 1 |
| Fukuda, H; Ishii, T; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Shimoyama, Y; Tanaka, K | 1 |
| Anel, A; Azaceta, G; Galán-Malo, P; Jarauta, V; López-Royuela, N; Marzo, I; Naval, J; Palomera, L; Pardo, J; Ramírez-Labrada, A | 1 |
| Baert, M; Chauffert, B; Diouf, M; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Saidak, Z | 1 |
| Barbare, JC; Bouhlal, H; Chatelain, D; Chauffert, B; Debuysscher, V; François, C; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Marcq, I; Saidak, Z | 1 |
| Chiba, T; Kanogawa, N; Kobayashi, K; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O | 1 |
| Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Conte, MA; Diouf, M; Galmiche, A; Ganne, N; Godin, C; Louandre, C; Saidak, Z; Trinchet, JC | 1 |
| Araki, H; Gotoh, M; Hattori, R; Kimura, T; Sassa, N; Tanaka, K; Tsuzuki, T; Yamada, S; Yoshino, Y | 1 |
| Baltatzis, G; Björklund, AC; Chioureas, D; Egevad, L; Fonseca, P; Gogvadze, V; Grandér, D; Kharaziha, P; Lennartsson, L; Nilsson, S; Panaretakis, T; Rodriguez, P; Zhivotovsky, B | 1 |
| Kim, do Y; Kim, GM; Kim, MD; Kim, SH; Lee, do Y; Park, SI; Shin, M; Shin, W; Won, JY | 1 |
| Cai, H; Kong, WT; Tang, Y; Wang, WP; Zhang, XL | 1 |
| Chishima, T; Dry, SM; Eilber, FC; Elliott, I; Endo, I; Federman, N; Hiroshima, Y; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Murakami, T; Nelson, SD; Russell, T; Singh, A; Tanaka, K; Yanagawa, J; Zhang, Y; Zhao, M | 1 |
| Chen, J; Fang, H; Jiang, B; Kang, M; Tang, Z; Wu, Y; Ye, Q; Zhang, B | 1 |
| Berg, CP; Bitzer, M; Claussen, CD; Gregor, M; Horger, M; Koppenhöfer, U; Lauer, UM; Schraml, C | 1 |
| Beynat, C; Coudert, B; Diaz, P; Favier, L; Ghiringhelli, F; Ladoire, S | 1 |
| Bitzer, M; Claussen, CD; Fenchel, M; Gregor, M; Horger, M; Lauer, UM; Spira, D | 1 |
| Bruners, P; Frei, P; Geier, A; Herweg, C; Mahnken, AH; Martin, IV; Mertens, JC; Müllhaupt, B; Schmitt, J | 1 |
| Liu, Q; Mier, JW; Panka, DJ | 1 |
| Artéaga, C; Brardjanian, S; Coton, T; Fabries, P; Guisset, M; Pauleau, G | 1 |
| Chan, CC; Huang, YT; Lee, KC; Lee, TY; Lin, HC; Yang, YY; Yeh, YC | 1 |
| Anichini, A; Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Mortarini, R | 1 |
1 review(s) available for sorafenib and Necrosis
| Article | Year |
|---|---|
Repurposing anticancer drugs for targeting necroptosis.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Drug Repositioning; Humans; Imidazoles; Indazoles; Necrosis; Oximes; Pyridazines; Pyrimidines; Reperfusion Injury; Sorafenib; Sulfonamides; Systemic Inflammatory Response Syndrome; Vemurafenib | 2018 |
30 other study(ies) available for sorafenib and Necrosis
| Article | Year |
|---|---|
Preparation of microspheres encapsulating sorafenib and catalase and their application in rabbit VX2 liver tumor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catalase; Cell Line, Tumor; Chemoembolization, Therapeutic; Drug Compounding; Female; Hydrogen Peroxide; Liver Neoplasms, Experimental; Male; Microspheres; Necrosis; Polylactic Acid-Polyglycolic Acid Copolymer; Rabbits; Sorafenib; Tumor Hypoxia; Tumor Microenvironment | 2020 |
Antiglioma Potential of Coumarins Combined with Sorafenib.
Topics: 4-Hydroxycoumarins; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Beclin-1; Caspase 3; Cell Line, Tumor; Cell Proliferation; Coumarins; Esculin; Gene Expression Regulation; Glioblastoma; Humans; Magnoliopsida; Necrosis; Phosphatidylinositol 3-Kinases; Plant Extracts; Proto-Oncogene Proteins c-bcl-2; raf Kinases; RNA, Small Interfering; Sorafenib; Umbelliferones | 2020 |
Ferroptosis and Cell Death Analysis by Flow Cytometry.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dactinomycin; Flow Cytometry; Humans; Indicators and Reagents; Iron; Necrosis; Niacinamide; Phenylurea Compounds; Piperazines; Propidium; Rats; Sorafenib | 2017 |
Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury.
Topics: Animals; Apoptosis; Cell Death; Disease Models, Animal; Humans; Inflammation; Mice; Necrosis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinases; Receptor-Interacting Protein Serine-Threonine Kinases; Reperfusion Injury; Sorafenib; Tumor Necrosis Factor-alpha | 2017 |
Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Cytochromes c; Electron Transport; Hep G2 Cells; Humans; Imidazoles; Lysosomes; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Mitophagy; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridazines; Pyridines; Sorafenib | 2018 |
Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma.
Topics: Animals; Biomarkers, Tumor; Capillary Permeability; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Hypoxia; Image Processing, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Imaging; Male; Necrosis; Neovascularization, Pathologic; Permeability; Rats; Sorafenib | 2019 |
Chemosensitivity and chemoresistance in endometriosis - differences for ectopic versus eutopic cells.
Topics: Adult; Aminobenzoates; Apoptosis; Caspase 3; Cell Survival; Cells, Cultured; Doxorubicin; Drug Resistance; Endometriosis; Endometrium; Epithelial Cells; Female; Humans; Necrosis; Oligopeptides; Oxadiazoles; Peritoneal Diseases; Sorafenib; Stromal Cells; Young Adult | 2019 |
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell Survival; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Humans; Lymphoma; MAP Kinase Signaling System; Mice; Mice, SCID; Necrosis; Neovascularization, Pathologic; Niacinamide; Pericytes; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor; Drug Therapy, Combination; Glioblastoma; Glioma; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Membrane Potential, Mitochondrial; Mitochondria; Molecular Chaperones; Necrosis; Niacinamide; Phenylurea Compounds; Quercetin; Sorafenib | 2014 |
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carbamates; Cell Line, Tumor; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Imidazoles; Indoles; Membrane Proteins; Mice; Mice, SCID; Necrosis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Reactive Oxygen Species; Sorafenib; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Contrast Media; Female; Humans; Liver Neoplasms; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase Inhibitors; Caspases; Cell Proliferation; Flow Cytometry; Humans; Mitochondria; Multiple Myeloma; Necrosis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sorafenib; Tumor Cells, Cultured | 2015 |
Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Humans; L-Lactate Dehydrogenase; Necrosis; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured | 2014 |
The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Female; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Necrosis; Niacinamide; Oxidative Stress; Phenylurea Compounds; Reactive Oxygen Species; Retinoblastoma Protein; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Necrosis; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Regional Blood Flow; Sorafenib; Vascular Access Devices | 2015 |
Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Keratin-18; Liver Neoplasms; Male; Necrosis; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2015 |
Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Grading; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Sorafenib | 2015 |
Sorafenib-induced defective autophagy promotes cell death by necroptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Blotting, Western; Cells, Cultured; Drug Resistance, Neoplasm; Embryo, Mammalian; Fibroblasts; Flow Cytometry; Humans; Immunoenzyme Techniques; Immunoprecipitation; Male; Mice; Mice, Knockout; Microtubule-Associated Proteins; Necrosis; Niacinamide; Phagosomes; Phenylurea Compounds; Prostatic Neoplasms; Receptor-Interacting Protein Serine-Threonine Kinases; RNA-Binding Proteins; Sorafenib; Tissue Array Analysis | 2015 |
Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiodized Oil; Feasibility Studies; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms, Experimental; Male; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rabbits; Sorafenib; Tissue Distribution; Vascular Endothelial Growth Factor A | 2016 |
Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model.
Topics: Animals; Catheter Ablation; Cell Line, Tumor; Chemotherapy, Adjuvant; Contrast Media; Diffusion Magnetic Resonance Imaging; Immunohistochemistry; Liver; Liver Neoplasms, Experimental; Microwaves; Necrosis; Neoplasm, Residual; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rabbits; Sorafenib; Ultrasonography | 2016 |
Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug.
Topics: Adolescent; Animals; Antineoplastic Agents; Biological Therapy; Bone Neoplasms; Drug Resistance, Neoplasm; Humans; Male; Mice, Nude; Molecular Targeted Therapy; Necrosis; Niacinamide; Osteosarcoma; Phenylurea Compounds; Protein Kinase Inhibitors; Salmonella typhimurium; Sorafenib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Mice; Necrosis; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2009 |
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcitonin; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Susceptibility; Everolimus; Fatal Outcome; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonia, Bacterial; Pneumothorax; Protein Precursors; Pyridines; Pyrroles; Rupture, Spontaneous; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2010 |
Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Follow-Up Studies; Gadolinium DTPA; Humans; Image Enhancement; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome; Tumor Burden | 2011 |
Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals.
Topics: Alanine Transaminase; Animals; Benzenesulfonates; Catheter Ablation; Cell Proliferation; Epidermal Growth Factor; Fluorescent Antibody Technique; Glutamate Dehydrogenase; Hepatocyte Growth Factor; Image Processing, Computer-Assisted; Liver; Male; Models, Animal; Necrosis; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Gene Expression; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Melanoma; Mice; Mice, Nude; Mitochondria; Necrosis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Transport; Proto-Oncogene Proteins c-mdm2; Pyridines; RNA Interference; Sorafenib; Spiro Compounds; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
[Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenal Glands; Antineoplastic Agents; Carcinoma, Hepatocellular; Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
Topics: Animals; Apoptosis; Disease Models, Animal; Fatty Liver; Gene Expression Regulation, Enzymologic; Hemodynamics; Inflammation; Liver; Male; MAP Kinase Signaling System; Necrosis; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Reperfusion Injury; rho-Associated Kinases; RNA, Messenger; Sorafenib; Transplantation, Homologous | 2012 |
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Mitogen-Activated Protein Kinases; Necrosis; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |